ProQR Therapeutics (PRQR) Competitors $2.37 -0.09 (-3.47%) As of 03:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRQR vs. TSHA, CRMD, URGN, RZLT, ABUS, PHAT, KOD, VALN, XNCR, and MNMDShould you be buying ProQR Therapeutics stock or one of its competitors? The main competitors of ProQR Therapeutics include Taysha Gene Therapies (TSHA), CorMedix (CRMD), Urogen Pharma (URGN), Rezolute (RZLT), Arbutus Biopharma (ABUS), Phathom Pharmaceuticals (PHAT), Kodiak Sciences (KOD), Valneva (VALN), Xencor (XNCR), and Mind Medicine (MindMed) (MNMD). These companies are all part of the "pharmaceutical products" industry. ProQR Therapeutics vs. Its Competitors Taysha Gene Therapies CorMedix Urogen Pharma Rezolute Arbutus Biopharma Phathom Pharmaceuticals Kodiak Sciences Valneva Xencor Mind Medicine (MindMed) Taysha Gene Therapies (NASDAQ:TSHA) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation. Does the media favor TSHA or PRQR? In the previous week, Taysha Gene Therapies had 26 more articles in the media than ProQR Therapeutics. MarketBeat recorded 27 mentions for Taysha Gene Therapies and 1 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 1.16 beat Taysha Gene Therapies' score of 0.39 indicating that ProQR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 3 Very Positive mention(s) 5 Positive mention(s) 16 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, TSHA or PRQR? Taysha Gene Therapies has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Is TSHA or PRQR more profitable? ProQR Therapeutics has a net margin of -238.52% compared to Taysha Gene Therapies' net margin of -1,144.97%. ProQR Therapeutics' return on equity of -61.25% beat Taysha Gene Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies-1,144.97% -78.44% -44.82% ProQR Therapeutics -238.52%-61.25%-28.13% Do analysts prefer TSHA or PRQR? Taysha Gene Therapies currently has a consensus price target of $9.00, suggesting a potential upside of 100.58%. ProQR Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 238.27%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe ProQR Therapeutics is more favorable than Taysha Gene Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Taysha Gene Therapies 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80ProQR Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Which has better earnings & valuation, TSHA or PRQR? ProQR Therapeutics has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTaysha Gene Therapies$8.33M146.95-$89.30M-$0.34-13.20ProQR Therapeutics$20.46M12.16-$30.04M-$0.46-5.14 Do insiders and institutionals have more ownership in TSHA or PRQR? 77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 3.8% of Taysha Gene Therapies shares are held by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryProQR Therapeutics beats Taysha Gene Therapies on 11 of the 17 factors compared between the two stocks. Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRQR vs. The Competition Export to ExcelMetricProQR TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$248.51M$3.33B$6.10B$10.63BDividend YieldN/A2.28%5.64%4.70%P/E Ratio-5.1322.1785.7027.12Price / Sales12.16265.55527.98206.41Price / CashN/A46.3226.3031.12Price / Book2.609.9612.896.68Net Income-$30.04M-$52.35M$3.30B$275.95M7 Day Performance7.99%6.14%4.68%3.35%1 Month Performance-3.47%11.80%7.99%10.81%1 Year Performance21.28%25.31%75.79%33.78% ProQR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRQRProQR Therapeutics2.3769 of 5 stars$2.37-3.5%$8.00+238.3%+25.6%$248.51M$20.46M-5.13180Positive NewsTSHATaysha Gene Therapies2.5567 of 5 stars$3.16-2.8%$8.29+162.2%+136.8%$886.58M$8.33M-9.29180News CoverageGap UpCRMDCorMedix3.1197 of 5 stars$11.85+4.9%$18.00+51.9%+27.4%$882.07M$121.48M15.8030Analyst DowngradeURGNUrogen Pharma3.9558 of 5 stars$19.14+4.4%$32.00+67.2%+37.0%$848.48M$90.40M-5.77200Analyst ForecastRZLTRezolute2.8282 of 5 stars$9.29-0.5%$14.50+56.1%+84.6%$848.18MN/A-9.5840ABUSArbutus Biopharma1.3787 of 5 stars$4.46+1.1%$5.00+12.1%+14.1%$845.39M$6.17M-15.3890Negative NewsPHATPhathom Pharmaceuticals1.9765 of 5 stars$11.33-3.8%$17.50+54.5%-29.2%$835.72M$55.25M-2.40110News CoverageGap UpKODKodiak Sciences3.0234 of 5 stars$15.81+0.1%$13.00-17.8%+466.2%$834.58MN/A-4.1690Analyst ForecastVALNValneva2.514 of 5 stars$10.95+12.8%$15.00+37.0%+96.0%$834.35M$183.52M-11.17700Gap UpXNCRXencor3.3666 of 5 stars$11.55-0.2%$22.25+92.6%-40.7%$825.21M$110.49M-4.81280Analyst ForecastGap UpMNMDMind Medicine (MindMed)2.3487 of 5 stars$12.04+12.8%$26.50+120.1%+125.5%$811.86MN/A-7.8740High Trading Volume Related Companies and Tools Related Companies Taysha Gene Therapies Competitors CorMedix Competitors Urogen Pharma Competitors Rezolute Competitors Arbutus Biopharma Competitors Phathom Pharmaceuticals Competitors Kodiak Sciences Competitors Valneva Competitors Xencor Competitors Mind Medicine (MindMed) Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRQR) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe Dollar’s Crashing—What Are You Doing About It?The U.S. dollar is down 10.8%—its steepest drop since 1973. As global confidence in the dollar fades, centr...Lear Capital | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
